STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma.
about
Contribution of classical end-joining to PTEN inactivation in p53-mediated glioblastoma formation and drug-resistant survival.Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells.Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptorAssessment of tumor response to tyrosine kinase inhibitorsMalignant gliomas: strategies to increase the effectiveness of targeted molecular treatment.Inhibiting kinases in malignant gliomas.Long-circulating near-infrared fluorescence core-cross-linked polymeric micelles: synthesis, characterization, and dual nuclear/optical imaging.Antiangiogenic therapy in brain tumors.Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.Designer therapies for glioblastoma multiforme.Current available therapies and future directions in the treatment of malignant gliomas.Tax-interacting protein 1 coordinates the spatiotemporal activation of Rho GTPases and regulates the infiltrative growth of human glioblastoma.New anti-angiogenic strategies in pediatric solid malignancies: agents and biomarkers of a near future.Targeting DNA repair and the cell cycle in glioblastoma.Malignant glioma drug discovery - targeting protein kinases.Enhancing radiation therapy for patients with glioblastoma.Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma.EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines.Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas.ERBB3, IGF1R, and TGFBR2 expression correlate with PDGFR expression in glioblastoma and participate in PDGFR inhibitor resistance of glioblastoma cells.
P2860
Q30363869-D51C8075-C8B3-4CB0-B156-07CAF206BB74Q33644407-C947165C-E286-4283-B9D9-F60433C42A50Q33651783-BD76612C-2D4F-446F-976F-4DBB807EF8C7Q33937769-F6F4FE6D-881F-4B74-9E5A-0140A0E419DFQ35558589-72344B10-B80B-4C11-864C-485089D74F81Q36499234-512EB0A9-842B-4DC4-A381-21CC3C3B3B1FQ36764876-B64C8ABC-EAFD-4124-9C1B-EE26EC38526CQ36891102-763C2FF8-506F-432B-ABD0-A567E1F12517Q37129915-D719717B-9761-4106-893F-73E797B4B120Q37308322-53009584-4FF8-43D7-A7E4-8D520759DAB9Q37319650-8D9EB311-368B-428D-BD14-F5D4ED636EE8Q37586907-14DD1B04-2202-4E91-A26E-F7B81C9122E3Q37662248-E7CF5A27-8666-4D3C-8417-89D0484C6539Q37752435-2937863E-65AF-4CE4-ACEA-01F408E6D390Q37960389-3C0FB996-8FEE-4447-A2C6-01BEFA9BAB40Q38089834-5054D544-B8DA-4324-9E1A-936DF11B131CQ38101608-1E44D6AF-77AF-4B5E-8C7E-E8DE782B2811Q38957729-03AF5E4B-3841-4D36-9DA3-4F95A31A2179Q41490623-7FF2BDB3-2DC2-4827-9F14-25C4BE093E38Q43290383-BCF51F19-B508-4265-A0EC-23DB28133B30Q55080493-349E35E2-B699-47E4-887E-3B1DC4B5E078
P2860
STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
STI571 (Gleevec) improves tumo ...... mouse models of glioblastoma.
@en
type
label
STI571 (Gleevec) improves tumo ...... mouse models of glioblastoma.
@en
prefLabel
STI571 (Gleevec) improves tumo ...... mouse models of glioblastoma.
@en
P2093
P1476
STI571 (Gleevec) improves tumo ...... mouse models of glioblastoma.
@en
P2093
Dennis E Hallahan
Eric T Shinohara
Jiahuai Tan
Kate Osusky
P304
P356
10.1016/J.IJROBP.2005.08.025
P407
P577
2005-11-07T00:00:00Z